BALLERUP, Denmark–(BUSINESS WIRE)–LEO Pharma today announced that it has finalized the acquisition of the strategic asset TMB-001 as well as certain other assets from Timber Pharmaceuticals following its chapter 11 bankruptcy filing. The TMB-001 project aims to develop a topical treatment for multiple moderate to severe subtypes of congenital ichthyosis – a skin disease with significant unmet need and no approved prescription therapies available. The TMB-001 project continues as planned and w
Business Wire Merger/Acquisition News
